Division of Gynecologic Surgery, Department of Obstetrics and Gynecology, Mayo Clinic, 200 1st St. SW, Rochester, MN 55905, USA.
Division of Gynecologic Surgery, Department of Obstetrics and Gynecology, Mayo Clinic, 200 1st St. SW, Rochester, MN 55905, USA.
Gynecol Oncol. 2020 May;157(2):476-481. doi: 10.1016/j.ygyno.2020.02.025. Epub 2020 Feb 24.
To report the impact of implementing standardized guidelines for opioid prescriptions after gynecologic surgery and describe patient perspectives before and after implementation for those undergoing laparotomy for ovarian cancer.
Patients undergoing gynecologic surgery between October 2017 and May 2018 were prescribed opioids at discharge using tiered guidelines; prescriptions were compared to consecutive historical controls (March 2017-October 2017). A subset of ovarian cancer laparotomy patients were surveyed regarding postoperative opioid consumption and patient experience.
A total of 620 women in the tiered guideline cohort were compared with 599 historical controls. Following implementation, 95.8% of prescriptions met guidelines. Median milligram morphine equivalents (MME) prescribed decreased from 150 to 75 (p ≤ 0.001) with no change in opioid refills (7.7 vs 6.9%, p = 0.62). In surveyed ovarian cancer patients, 100% of tiered guideline patients and 92% of historical controls felt satisfied with pain control (p = 0.24), despite a 50% reduction in prescribed MME and 14.6% receiving no opioids at discharge (p = 0.002). The median (IQR) MME consumed after discharge was 15 (0, 75) in tiered guideline patients vs. 24 (0, 135) in historical controls, and 38.2% and 42.4% consumed no opioids, respectively. Mean time between surgery and opioid use cessation was <1 week in both groups; patients' perceptions of opioid prescription appropriateness did not change (p = 0.49). More than 75% of patients kept their remaining opioids rather than dispose of them.
Reducing prescribed opioids after gynecologic surgery using tiered guidelines did not increase opioid refills or worsen patients' perceptions of postoperative pain. Even after laparotomy, very little opioids were required over a short duration after dismissal. Infrequent disposal of leftover opioids highlights the need to avoid over-prescribing.
报告妇科手术后实施阿片类药物处方标准化指南的影响,并描述卵巢癌剖腹手术患者实施前后的患者观点。
2017 年 10 月至 2018 年 5 月期间接受妇科手术的患者在出院时根据分级指南开具阿片类药物;将这些处方与连续的历史对照(2017 年 3 月至 2017 年 10 月)进行比较。对卵巢癌剖腹手术患者进行了一项关于术后阿片类药物使用和患者体验的调查。
分层指南组共 620 例女性与 599 例历史对照组进行比较。实施后,95.8%的处方符合指南。规定的吗啡毫克当量中位数(MME)从 150 降至 75(p≤0.001),而阿片类药物的补充没有变化(7.7%对 6.9%,p=0.62)。在接受调查的卵巢癌患者中,100%的分层指南患者和 92%的历史对照患者对疼痛控制感到满意(p=0.24),尽管规定的 MME 减少了 50%,且 14.6%的患者在出院时未使用阿片类药物(p=0.002)。出院后消耗的 MME 中位数(IQR)在分层指南患者中为 15(0,75),在历史对照患者中为 24(0,135),分别有 38.2%和 42.4%的患者未使用阿片类药物。两组患者从手术到停止使用阿片类药物的平均时间均小于 1 周;患者对阿片类药物处方的适当性的看法没有改变(p=0.49)。超过 75%的患者保留了剩余的阿片类药物,而不是将其丢弃。
使用分级指南减少妇科手术后开具的阿片类药物并没有增加阿片类药物的补充或加重患者对术后疼痛的感知。即使进行了剖腹手术,在出院后很短的时间内也只需要很少的阿片类药物。很少有剩余的阿片类药物被丢弃,这突出表明需要避免过度处方。